Prof. Yingfen Ying | Tumors | Women Researcher Award

Posted on 06/01/202506/01/2025 by Pencis

Prof. Yingfen Ying | Tumors | Women Researcher Award

Wenzhou Medical University | China

AUTHOR PROFILE

PROFESSOR YINGFEN YING: A DISTINGUISHED MEDICAL PROFESSIONAL 👩‍⚕️🌍

EARLY ACADEMIC PURSUITS 🎓✨

Professor Yingfen Ying embarked on her academic journey with a strong focus on medical sciences, demonstrating an early aptitude for research and clinical excellence. Her academic foundation was fortified through rigorous education at Wenzhou Medical University, where she gained critical knowledge and skills that paved the way for her distinguished career. She further enriched her expertise as a visiting scholar at the University of British Columbia in Canada, a testament to her global academic vision.

PROFESSIONAL ENDEAVORS 💼🏥

Professor Ying has made significant strides as an Associate Chief Physician and master’s supervisor at Wenzhou Medical University. Her roles extend to various esteemed positions, including:

Member of the Obstetrics and Gynecology Rehabilitation Committee, Chinese Rehabilitation Medicine Association.
Vice Chairwoman of the Youth Committee, Reproductive Medicine Branch, Zhejiang Society of Traditional Chinese and Western Medicine.
Member of the Obstetrics and Gynecology Branch, Zhejiang Society of Translational Medicine.
She is also affiliated with prominent international organizations, such as the American Society of Reproductive Medicine and the European Society of Human Reproduction and Embryology.

CONTRIBUTIONS AND RESEARCH FOCUS 🔬📚

Professor Ying’s primary research interests center on the mechanistic study of environmental endocrine disruptors and reproductive endocrine diseases. Her investigations delve into the interplay between environmental factors and hormonal imbalances, significantly advancing our understanding of infertility diseases. She has led multiple national and international research projects, including those funded by the National Natural Science Foundation of China.

IMPACT AND INFLUENCE 🌟🌏

Professor Ying’s work has had far-reaching impacts in the field of reproductive medicine. She has authored nearly 30 SCI-indexed papers, contributing valuable insights and advancements to the global medical community. Her research continues to influence clinical practices and guide innovative therapeutic approaches for infertility.

ACADEMIC CITES AND PATENT ACHIEVEMENTS 📜🔑

Professor Ying’s extensive research portfolio has garnered numerous citations in high-impact journals. Additionally, she holds a European patent, exemplifying her contributions to advancing medical technology and treatment methodologies on a global scale.

LEGACY AND FUTURE CONTRIBUTIONS 🌟🚀

As a trailblazer in reproductive medicine, Professor Yingfen Ying’s legacy is defined by her commitment to advancing medical science, mentoring future generations, and improving patient outcomes. Her ongoing projects and international collaborations promise continued breakthroughs, ensuring her work remains at the forefront of reproductive health and endocrine research.

ADDITIONAL HIGHLIGHTS 🌐📖

Active member of youth committees in Zhejiang’s medical and scientific communities, fostering innovation and development among emerging scholars.
Her dedication to integrating traditional Chinese and Western medicine highlights a holistic approach to patient care and research.
International affiliations reflect her commitment to global medical advancements, strengthening ties between diverse medical communities.

CONCLUSION 🌟🏆

Professor Yingfen Ying exemplifies excellence in the fields of reproductive medicine and endocrine research. Her dedication to uncovering the mechanisms of infertility diseases and environmental endocrine disruptors has advanced both science and clinical practice. Through her leadership roles, impactful publications, and international collaborations, she has established herself as a global authority and advocate for holistic and innovative approaches to healthcare.

📊🔬NOTABLE PUBLICATION:

Title: Halogen atoms determine the inhibitory potency of halogenated bisphenol A derivatives on human and rat placental 11β-hydroxysteroid dehydrogenase 2
Authors: Shi, L., Zhang, B., Ying, Y., Ge, R.-S., Liu, Y.
Journal: Food and Chemical Toxicology
Year: 2023

Title: Inhibitory effects of parabens on human and rat 17β-hydroxysteroid dehydrogenase 1: Mechanisms of action and impact on hormone synthesis
Authors: Chen, Z., Gong, C., Tang, Y., Ge, R.-S., Ying, Y.
Journal: Toxicology
Year: 2024

Title: Per- and polyfluoroalkyl substances inhibit human and rat 17β-hydroxysteroid dehydrogenase 1: Quantitative structure-activity relationship and molecular docking analysis
Authors: Wen, C., Chen, H., Tang, Y., Chen, C., Chen, S.
Journal: Ecotoxicology and Environmental Safety
Year: 2024

Title: Leydig cell development in pubertal male rats is blocked by perfluorotetradecanoic acid through decreasing AMPK-mTOR-autophagy pathway
Authors: Tang, Y., Shi, L., Wang, S., Ge, R.-S., Ying, Y.
Journal: Toxicology Letters
Year: 2023

Title: Structure-activity relationship and in silico docking analysis of dicarboximide fungicides on 17β-hydroxysteroid dehydrogenase 1 of human, rat, and pig
Authors: Chen, H., Chen, S., Tang, Y., Ge, R.-S., Duan, P.
Journal: Ecotoxicology and Environmental Safety
Year: 2025

Dr. Yuta Yamanaka | Lung Cancer | Best Researcher Award

Posted on 21/09/202421/09/2024 by Pencis

Dr. Yuta Yamanaka | Lung Cancer | Best Researcher Award

Kansai Medical University Hospital | Japan

AUTHOR PROFILE

Scopus

ORCID Id

🧑‍🎓 EARLY ACADEMIC PURSUITS 📚

Dr. Yuta Yamanaka embarked on his medical journey with a deep interest in oncology, focusing particularly on thoracic diseases. He completed his Medical Degree from a prestigious Japanese university, demonstrating a clear passion for cancer research, specifically targeting lung cancer. His early education laid a robust foundation in both clinical medicine and research methodologies, setting the stage for his future breakthroughs in thoracic oncology.

🩺 PROFESSIONAL ENDEAVORS 🏥

Dr. Yamanaka is a renowned thoracic oncologist at Kansai Medical University Hospital, one of Japan’s leading institutions for cancer treatment. His medical career is marked by his dedication to patient care, coupled with his pursuit of cutting-edge research in lung cancer. As a departmental leader, Dr. Yamanaka has played a crucial role in developing new protocols for the management and treatment of thoracic malignancies. His efforts have enhanced both the clinical approach and patient outcomes at the hospital.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON LUNG CANCER🔍

Dr. Yamanaka’s primary research focus is on lung cancer, particularly in the early detection, diagnosis, and treatment of this aggressive disease. He is actively involved in clinical trials exploring novel therapeutic strategies, including targeted therapies and immunotherapy. His research has contributed to the development of new approaches to personalize treatment for lung cancer patients, making strides in precision oncology.

Additionally, Dr. Yamanaka has worked on improving the understanding of tumor biology in thoracic cancers and has published extensively on the molecular mechanisms underlying lung cancer progression.

🌍 IMPACT AND INFLUENCE 💡

Dr. Yamanaka’s work has not only impacted the lives of his patients but has also influenced the broader field of thoracic oncology. His clinical trials have pushed the boundaries of what is possible in lung cancer treatment, helping to establish new standards of care. Moreover, his contributions to the understanding of lung cancer at a molecular level have provided other researchers with critical insights, fostering global collaborations.

🏆 ACADEMIC CITES AND RECOGNITION 📜

Dr. Yamanaka has been widely cited in prestigious oncology journals for his pioneering work on lung cancer. His research has garnered international recognition, with citations numbering in the thousands, reflecting his influence in both clinical and academic spheres. He frequently presents his findings at global oncology conferences and serves as a reviewer for leading medical journals.

🔮 LEGACY AND FUTURE CONTRIBUTIONS 🌟

Looking forward, Dr. Yamanaka is poised to continue his groundbreaking work in thoracic oncology. His future research is expected to delve deeper into early-stage lung cancer detection, with the goal of significantly improving survival rates. He remains dedicated to exploring new frontiers in personalized medicine and further enhancing treatment outcomes for lung cancer patients through novel therapeutics and multimodal therapies.

Dr. Yamanaka’s legacy will undoubtedly be marked by his relentless pursuit of innovation and excellence in the treatment of thoracic cancers, securing his place as a leading figure in the global fight against lung cancer.

Dr. Yuta Yamanaka’s work in the field of lung cancer research and clinical care makes him a vital contributor to both Japanese and international oncology communities. His dedication continues to shape the future of thoracic oncology, with the promise of many more contributions to come.

✨ CONCLUSION 🎯

Dr. Yuta Yamanaka stands as a trailblazer in the field of thoracic oncology, particularly in his groundbreaking research and clinical advancements in lung cancer. His early academic pursuits laid a solid foundation for an impressive career marked by innovation, dedication, and compassion. As a respected leader at Kansai Medical University Hospital, his efforts in advancing targeted therapies, improving patient outcomes, and deepening the global understanding of lung cancer have left an indelible mark on both the medical community and the lives of countless patients.

📊🔬NOTABLE PUBLICATION:

Clinical significance of factor XIII activity and monocyte-derived microparticles in cancer patients

Authors: Sawai, Y., Yamanaka, Y., Nomura, S.

Journal: Vascular Health and Risk Management

Year: 2020

Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study

Authors: Takeda, T., Yamada, T., Kunimatsu, Y., Kurata, T., Takayama, K.

Journal: Cancers

Year: 2023

Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older

Authors: Yagishita, S., Yamanaka, Y., Kurata, T., Mizugaki, H., Hamada, A.

Journal: Clinical Pharmacology and Therapeutics

Year: 2024

Paraneoplastic Neurological Syndrome-associated Antibody-positive Small-cell Lung Cancer Diagnosed with Preceding Neurological Symptoms: a Case Series

Authors: Okazaki, Y., Yoshioka, H., Kamisako, K., Yamanaka, Y., Kurata, T.

Journal: Japanese Journal of Lung Cancer

Year: 2024

Investigation of a practical assessment index to capture the clinical presentation of cachexia in patients with lung cancer

Authors: Katsushima, U., Hase, K., Fukushima, T., Imai, Y., Kurata, T.

Journal: Japanese Journal of Clinical Oncology

Year: 2024

Prof. R. StephanieHuang – Oncology and Precision Medicine – Best Researcher Award

Posted on 03/05/202403/05/2024 by Pencis

Prof. R. StephanieHuang - Oncology and Precision Medicine - Best Researcher Award

University Of Minnesota - Minneapolis, MN - United States

Author Profile

Scopus

Orcid

Early Academic Pursuits

Dr. Rong Stephanie Huang's academic journey began with her pursuit of pharmacology at the University of Minnesota, where she eventually earned the title of Distinguished McKnight University Professor. Her early academic pursuits laid the foundation for her distinguished career in the field.

Professional Endeavors

Throughout her career, Dr. Huang has held prestigious academic appointments, including her current position in the Department of Experimental and Clinical Pharmacology at the University of Minnesota. Her commitment to advancing pharmacology is evident in her leadership roles and contributions to various professional societies.

Contributions and Research Focus on Oncology and Precision Medicine

Dr. Huang's research primarily focuses on personalized and precision medicine, particularly in oncology. Her work aims to tailor treatments to individual patients by understanding the genetic and molecular mechanisms underlying cancer progression. This research has significant implications for improving patient outcomes in cancer treatment.

Impact and Influence

As a respected leader in pharmacology, Dr. Huang's influence extends beyond her research. Her leadership roles in organizations such as the International Pharmaceutical Federation (FIP) highlight her dedication to advancing the field on a global scale. Her contributions have shaped the landscape of personalized medicine and oncology research.

Academic Citations

Dr. Huang's research has garnered substantial attention within the academic community, evidenced by the numerous citations her work has received. Her findings have contributed to advancing knowledge in pharmacology, particularly in the realm of personalized medicine and cancer research.

Legacy and Future Contributions

Dr. Huang's legacy is characterized by her significant contributions to pharmacology and personalized medicine. Her ongoing leadership roles and mentorship efforts ensure that her impact will endure for future generations of pharmacologists. As she continues her research and advocacy, Dr. Huang will undoubtedly leave a lasting legacy in the field.

Notable Publications

A systematic review on sex differences in adverse drug reactions related to psychotropic, cardiovascular, and analgesic medications.

Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis.

Integration of Computational Pipeline to Streamline Efficacious Drug Nomination and Biomarker Discovery in Glioblastoma.

Integration of pan-cancer cell line and single-cell transcriptomic profiles enables inference of therapeutic vulnerabilities in heterogeneous tumors.

A review of computational methods for predicting cancer drug response at the single-cell level through integration with bulk RNAseq data.

Dr. Durre Nayab – Cancer Research – Best Researcher Award

Posted on 27/02/202428/02/2024 by Pencis

Dr. Durre Nayab - Cancer Research - Best Researcher Award

Technische Universitat Dresden - Germany

AUTHOR PROFILE

Google Scholar

EARLY ACADEMIC PURSUITS:

Durr-e-Nayab's academic journey began with a Bachelor's degree in Computer Systems Engineering from the University of Engineering and Technology, Peshawar, Pakistan, followed by a Master's in Computer Systems Engineering from the same institution. Later, she achieved a Ph.D. in Electrical Engineering from the University of Engineering and Technology, Peshawar, with a research focus on Adaptive Expanding Ring Search Based Per Hop Routing Rendition in Mobile Ad Hoc Networks (MANETs) using Machine Learning.

PROFESSIONAL ENDEAVORS:

Nayab has accumulated 11 years of teaching experience and 6 years of research experience. She has held various positions, including Lecturer & Batch Advisor at the University of Engineering and Technology, Peshawar, and Research Assistant at the Center for Intelligent Systems and Networks Research. Additionally, she has served as a Lecturer in Computer Science at City University of Science and Technology and Institute of Business and Management Sciences.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER RESEARCH

Her contributions extend to research projects, including a significant role as a Research Assistant in R & D Funded Projects at the Center for Intelligent Systems and Networks Research. Notable projects involve secure and intelligent transportation systems, secure billing frameworks, traffic pattern analysis, and autonomous situation-based alerts using wireless sensor networks.

IMPACT AND INFLUENCE:

Dr. Nayab's impact is evident through her contributions to projects funded by ICT R & D, Ministry of IT Pakistan, addressing critical issues such as congestion control, electricity theft, and traffic patterns in Pakistan. Her role as a Co-PI at the National Center for Artificial Intelligence showcases her influence in shaping intelligent systems design in Pakistan.

ACADEMIC CITES:

Dr. Nayab's research has made a substantial impact, with publications in reputable journals, including "Applied Computational Intelligence and Soft Computing," "Annals of Telecommunication," and "Computers, Materials & Continua."

LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Nayab's legacy is marked by her dedication to research and education, particularly in the fields of Mobile Ad Hoc Networks, Machine Learning, and Artificial Intelligence. Her future contributions are anticipated in her role as a Post-Doctoral Researcher at TU Dresden, focusing on Transport Modeling, Cancer Research and Simulation.

NOTABLE PUBLICATIONS

Performance Augmentation of Base Classifiers Using Adaptive Boosting Framework for Medical Datasets. 2023

Effects of dataset attacks on machine learning models in E-health. 2023

SP-DSTS-MIMO Scheme aided H.266 for reliable high data-rate mobile video-communication. 2023

Data Augmentation and Random Multi-Model Deep Learning for Data Classification. 2022

Sparse Crowd Flow Analysis of Tawaaf of Kaaba during the COVID-19 Pandemic. 2022

Cancer Drugs and Vaccines

Posted on 07/10/202313/10/2023 by Pencis

Cancer Drugs and Vaccines

Introduction: Cancer Drugs and Vaccines are at the forefront of oncology research and treatment, offering promising solutions in the fight against cancer. These innovative therapies aim to improve patient outcomes, enhance survival rates, and provide hope for individuals battling this devastating disease.

Subtopics in Cancer Drugs and Vaccines:

Immunotherapy in Cancer Treatment: Immunotherapy harnesses the power of the immune system to target and destroy cancer cells. Explore the latest developments in checkpoint inhibitors, CAR-T cell therapy, and immune checkpoint blockade.

Targeted Therapies: Targeted cancer drugs are designed to specifically target cancer cells with minimal damage to healthy tissues. Delve into the mechanisms and effectiveness of these precision therapies.

Vaccine-Based Approaches: Investigate the role of cancer vaccines in preventing or treating various types of cancer. Discover the development and clinical trials of vaccines that stimulate the immune system to recognize and combat cancer cells.

Combination Therapies: Combinatorial approaches involving a mix of drugs, vaccines, and other treatments are gaining traction. Explore how these synergistic combinations are revolutionizing cancer care.

Personalized Medicine: Learn about the concept of tailoring cancer treatments to individual patients based on their genetic and molecular profiles. Explore the advancements in genomic medicine and its impact on cancer drug development.

Resistance Mechanisms: Understand the challenges posed by drug resistance in cancer treatment and how researchers are addressing these issues through innovative strategies.

Emerging Biomarkers: Discover the latest biomarkers used in cancer diagnosis, prognosis, and treatment selection, paving the way for more personalized and effective therapies.

Clinical Trials and Regulatory Challenges: Examine the critical role of clinical trials in evaluating the safety and efficacy of cancer drugs and vaccines, along with the regulatory processes that govern their approval.

Future Trends in Cancer Therapeutics: Explore the cutting-edge technologies and trends shaping the future of cancer treatment, from nanomedicine to gene editing and beyond.

Patient Perspectives and Support: Consider the holistic approach to cancer care, including patient support systems, psychosocial aspects, and quality of life improvements alongside drug and vaccine development.